Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib.

World J Surg Oncol 2013 Aug 2;11(1):171. Epub 2013 Aug 2.

Department of Digestive Surgery, Rouen University Hospital, 1 Rue de Germont, 76031 Rouen, France.

Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients. We describe the case of a patient who presented with a large HCC in the left liver associated with portal vein thrombosis (PVT). After 9 months of sorafenib treatment, reassessment showed that the tumors had decreased in size with recanalization of the portal vein. A lateral left hepatectomy was performed and pathology showed complete necrosis of the tumor. Sorafenib can downstage HCC in patients with cirrhosis allowing further surgical resection.

Download full-text PDF

Source
http://dx.doi.org/10.1186/1477-7819-11-171DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735470PMC
August 2013

Publication Analysis

Top Keywords

portal vein
12
hepatocellular carcinoma
8
vein thrombosis
8
months sorafenib
4
sorafenib treatment
4
reassessment tumors
4
size recanalization
4
decreased size
4
tumors decreased
4
treatment reassessment
4
thrombosis pvt
4
presented large
4
patient presented
4
case patient
4
large hcc
4
left liver
4
recanalization portal
4
associated portal
4
liver associated
4
pvt months
4

Similar Publications